Palliative resections versus palliative bypass procedures in pancreatic cancera systematic review

American Journal of Surgery

Volumn 203, Issue 4, 2012, Pages 496-502

  Gillen, Sonja ^a   Schuster, Tibor ^b   Friess, Helmut ^a   Kleeff, Jrg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Morbidity; Mortality; Palliative; Pancreatic cancer; Resection; Tumor debulking

Indexed keywords

BYPASS SURGERY; CANCER PALLIATIVE THERAPY; CANCER SURGERY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL (TOPIC); GASTROJEJUNOSTOMY; HEPATOJEJUNOSTOMY; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; META ANALYSIS; MORBIDITY; MORTALITY; OPERATION DURATION; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGICAL TECHNIQUE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR DEBULKING;

BILIOPANCREATIC DIVERSION; FEMALE; HUMANS; MALE; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICOJEJUNOSTOMY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84859104258     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2011.05.004     Document Type: Review

References (26)

1. S. Gillen, T. Schuster, C. Meyer Zum Buschenfelde Preoperative/ neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med 7 2010 e1000267
2. H.G. Smeenk, T.C. Tran, J. Erdmann Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg 390 2005 94 103
3. M.A. Tempero, J.P. Arnoletti, S. Behrman Pancreatic adenocarcinoma J Natl Compr Canc Netw 8 2010 972 1017
4. G. Adler, T. Seufferlein, S.C. Bischoff S3-guidelines "exocrine pancreatic cancer 2007 [article in German] Z Gastroenterol 45 2007 487 523
5. D.J. Gouma, R. van Geenen, T. van Gulik Surgical palliative treatment in bilio-pancreatic malignancy Ann Oncol 10 suppl 1999 269 272
6. M. Tempero, J.P. Arnoletti, E. Ben-Josef Pancreatic adenocarcinoma Clinical practice guidelines in oncology J Natl Compr Canc Netw 5 2007 998 1033
7. E.L. Eisenhauer, N.R. Abu-Rustum, Y. Sonoda The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer Gynecol Oncol 103 2006 1083 1090
8. V. Margulis, S.F. Matin, C.G. Wood Cytoreductive nephrectomy in metastatic renal cell carcinoma Curr Opin Urol 18 2008 474 480
9. A.J. Pantuck, A.S. Belldegrun, R.A. Figlin Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res 13 2007 693s 696s
10. K.K. Shih, D.S. Chi Maximal cytoreductive effort in epithelial ovarian cancer surgery J Gynecol Oncol 21 2010 75 80
11. G.K. Abou-Alfa, R. Letourneau, G. Harker Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer J Clin Oncol 24 2006 4441 4447
12. G. Colucci, F. Giuliani, V. Gebbia Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale Cancer 94 2002 902 910
13. L. Dahan, F. Bonnetain, M. Ychou Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) Gut 59 2010 1527 1534
14. V. Heinemann, D. Quietzsch, F. Gieseler Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 2006 3946 3952
15. C.M. Rocha Lima, M.R. Green, R. Rotche Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 2004 3776 3783
16. H.H. Wong, N.R. Lemoine Pancreatic cancer: molecular pathogenesis and new therapeutic targets Nat Rev Gastroenterol Hepatol 6 2009 412 422
17. J.H. Klinkenbijl, J. Jeekel, P.I. Schmitz Carcinoma of the pancreas and periampullary region: palliation versus cure Br J Surg 80 1993 1575 1578
18. M.E. Reinders, J.H. Allema, T.M. van Gulik Outcome of microscopically nonradical, subtotal pancreaticoduodenectomy (Whipple's resection) for treatment of pancreatic head tumors World J Surg 19 1995 410 414
19. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
20. R. DerSimonian, N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
21. M. Bockhorn, G. Cataldegirmen, A. Kutup Crossing the Rubicon: when pancreatic resection with curative intent ends in an R2 status Impact of "desmoplastic pseudo-pancreatitis" and anatomical site of irresectability Ann Surg Oncol 16 2009 1212 1221
22. J. Kninger, M.N. Wente, B.P. Muller-Stich R2 resection in pancreatic cancerdoes it make sense? Langenbecks Arch Surg 393 2008 929 934
23. B. Schniewind, B. Bestmann, R. Kurdow Bypass surgery versus palliative pancreaticoduodenectomy in patients with advanced ductal adenocarcinoma of the pancreatic head, with an emphasis on quality of life analyses Ann Surg Oncol 13 2006 1403 1411
24. M. Tachezy, M. Bockhorn, F. Gebauer Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil? J Gastrointest Surg 15 2011 829 835
25. C.P. Raut, J.F. Tseng, C.C. Sun Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma Ann Surg 246 2007 52 60
26. D.J. Gouma, E.J. Nieveen van Dijkum, R.C. van Geenen Are there indications for palliative resection in pancreatic cancer? World J Surg 23 1999 954 959